CytoSorbents Corporation to Exhibit at the Advanced Technology Applications for Combat Casualty Care Conference
MONMOUTH JUNCTION, N.J., Aug. 4, 2011 /PRNewswire/ -- CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company using blood purification to treat life-threatening illnesses, announced that it is exhibiting at the Advanced Technology Applications for Combat Casualty Care (ATACCC) Conference to be held at the Marriott Harbor Beach Conference Center in Fort Lauderdale, Florida. CytoSorbents will be exhibiting from August 15-18, 2011 in Booth #60. ATACCC is the Department of Defenses' premier scientific meeting that addresses critical advances in trauma medicine and the unique medical needs of the warfighter ( https://www.ataccc.org/). The conference is attended by many of the top national and international military healthcare leaders and physicians and reports on best practices for the treatment of combat related injuries.
Dr. Phillip Chan, Chief Executive Officer and President, commented, "When we exhibited at ATACCC last year, our CytoSorb™ cytokine filter technology generated a lot of interest and enthusiasm, as it was specifically designed to help address the excessive inflammatory component associated with major injuries that our warfighters sustain in combat including polytrauma, infection and sepsis, and burns. This inflammation, driven by cytokine storm, can often lead to multiple organ failure, one of the leading causes of death in critically injured patients. Our clinical trial in sepsis patients and our European regulatory approval for CytoSorb™ have validated the technology as a safe and effective cytokine filter that can be used in life-threatening illnesses. This now opens up many more opportunities for us, particularly for European military applications, which we will actively pursue."
Dr. Chan concluded, "Over the past year, we have also been invited to present our technology to many different groups closely i